Gordon Ralph Corey, MD

Professor of Medicine
Gary Hock Professor in Global Health, in the School of Medicine
Vice-Chair for Education and Global Health in the Department of Medicine
Research Professor of Global Health
Professor of Pathology
Member in the Duke Clinical Research Institute
Campus mail 310 Trent Drive Room 235 Trent, Box 90519, Durham, NC 27708
Phone (919) 668-7174
Email address corey001@mc.duke.edu

My research is based at the Duke Clinical Research Institute, a large academic clinical research organization designed to conduct clinical trials from small local studies to worldwide trials. The focus of my research is bacterial infections: complicated skin and skin structure infections; postoperative wound infections; hospital-acquired and ventilator-associated pneumonia; bacteremia; and endocarditis. Many of these trials are conducted in concert with the pharmaceutical industry in order to register new antibiotics. In addition, as director of infectious diseases at the DCRI I oversee the work of the mycology group, and tuberculosis trials. This work also includes work supported by NIH grants including sepsis trials, the Staph Aureus and Staph Epi Bacteremia Groups, and the International Collaboration of Endocarditis. The team of investigators with whom I work is highly experienced, amazingly productive and wonderfully collegial.

As a result of my longstanding interest in tropical medicine and the generosity of my patients as well as the Hubert Family we have been able to establish the Hubert-Yeargan Center for Global Health. As a result we have developed a medical center-wide fellowship in Global Health. I am presently the Director of the Center and the Gary Hock Distinguished Professor of Global Health.

Education and Training

  • Fellowship, Infectious Diseases, Duke University School of Medicine, 1978 - 1980
  • Chief Resident, General Internal Medicine, Duke University School of Medicine, 1977 - 1978
  • Residency, General Internal Medicine, Duke University School of Medicine, 1975 - 1977
  • Internship, General Internal Medicine, Duke University School of Medicine, 1974 - 1975
  • M.D., Baylor University, 1973

Publications

Huang, David B., Stephanie Noviello, Barbara Balser, Amy Scaramucci, and G Ralph Corey. “A Pooled Analysis of the Safety and Efficacy of Iclaprim Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Patients With Intravenous Drug Use: Phase 3 REVIVE Studies..” Clin Ther 41, no. 6 (June 2019): 1090–96. https://doi.org/10.1016/j.clinthera.2019.04.004.

PMID
31030995
Full Text

Holland, Thomas L., Henry F. Chambers, Helen W. Boucher, G Ralph Corey, Rebecca Coleman, Bibiana Castaneda-Ruiz, and Vance G. Fowler. “Considerations for Clinical Trials of Staphylococcus aureus Bloodstream Infection in Adults..” Clin Infect Dis 68, no. 5 (February 15, 2019): 865–72. https://doi.org/10.1093/cid/ciy774.

PMID
30202941
Full Text

Huang, David B., Sophie Magnet, Stefania De Angelis, Thomas L. Holland, Thomas M. File, Matthew Dryden, G Ralph Corey, Antoni Torres, and Mark H. Wilcox. “Surveillance of iclaprim activity: in vitro susceptibility of Gram-positive skin infection pathogens collected from 2015 to 2016 from North America and Europe..” Diagn Microbiol Infect Dis 93, no. 2 (February 2019): 154–58. https://doi.org/10.1016/j.diagmicrobio.2018.09.002.

PMID
30266399
Full Text

Noviello, Stephanie, David B. Huang, and G Ralph Corey. “Iclaprim: a differentiated option for the treatment of skin and skin structure infections..” Expert Rev Anti Infect Ther 16, no. 11 (November 2018): 793–803. https://doi.org/10.1080/14787210.2018.1536545.

PMID
30317894
Full Text

Huang, David B., G Ralph Corey, Thomas L. Holland, Thomas Lodise, William O’Riordan, Mark H. Wilcox, Thomas M. File, et al. “Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections..” Int J Antimicrob Agents 52, no. 2 (August 2018): 233–40. https://doi.org/10.1016/j.ijantimicag.2018.05.012.

PMID
29783024
Full Text

Holland, Thomas L., William O’Riordan, Alison McManus, Elliot Shin, Ali Borghei, Thomas M. File, Mark H. Wilcox, et al. “A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study)..” Antimicrob Agents Chemother 62, no. 5 (May 2018). https://doi.org/10.1128/AAC.02580-17.

PMID
29530858
Full Text

Huang, David B., William O’Riordan, J Scott Overcash, Barry Heller, Faisal Amin, Thomas M. File, Mark H. Wilcox, et al. “A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Iclaprim Vs Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed to be Due to Gram-Positive Pathogens: REVIVE-1..” Clin Infect Dis 66, no. 8 (April 3, 2018): 1222–29. https://doi.org/10.1093/cid/cix987.

PMID
29281036
Full Text

Huang, David B., Thomas M. File, Matthew Dryden, G Ralph Corey, Antoni Torres, and Mark H. Wilcox. “Surveillance of iclaprim activity: In vitro susceptibility of gram-positive pathogens collected from 2012 to 2014 from the United States, Asia Pacific, Latin American and Europe..” Diagn Microbiol Infect Dis 90, no. 4 (April 2018): 329–34. https://doi.org/10.1016/j.diagmicrobio.2017.12.001.

PMID
29306582
Full Text

Corey, G Ralph, Jeffery Loutit, Greg Moeck, Matthew Wikler, Michael N. Dudley, William O’Riordan, and William SOLO I and SOLO II investigators. “Single Intravenous Dose of Oritavancin for Treatment of Acute Skin and Skin Structure Infections Caused by Gram-Positive Bacteria: Summary of Safety Analysis from the Phase 3 SOLO Studies..” Antimicrob Agents Chemother 62, no. 4 (April 2018). https://doi.org/10.1128/AAC.01919-17.

PMID
29358292
Full Text

Huang, David B., Leonard R. Duncan, Robert K. Flamm, Matthew Dryden, G Ralph Corey, Mark H. Wilcox, Antoni Torres, and Thomas M. File. “The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens..” Diagn Microbiol Infect Dis 90, no. 1 (January 2018): 64–66. https://doi.org/10.1016/j.diagmicrobio.2017.09.011.

PMID
29103875
Full Text

Pages